Company Overview
Who We Are
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines.
Unlike other drug discovery startups, BioSymetrics utilizes electronic health record data and human-relevant disease models to bring clinical insights, validated in vivo, into the scientific discovery process. BioSymetrics then applies its patent pending Contingent AI to denoise, debias and integrate this clinical data for use across a phenotype-driven, therapeutic discovery process.
We are a remote-first company with people clusters in Boston and Toronto.
Team
Our team is a diverse group of proven entrepreneurs, machine learning experts and R&D innovators. Our Scientific Advisory Board includes renowned scientists and technologists each with highly relevant expertise to our vision to advance precision medicines using data, machine learning and in vivo validation.
View Our Team
Machine Learning Technology
Contingent-AI™ is a patent pending automated iteration framework that addresses bias detection and correction during pre-processing stages of machine learning. The proprietary AI identifies additional feature sets for analysis that are contingent upon decisions made during bias reduction.
Machine learning technology is used with an experimental practice that allows BioSymetrics to uniquely combine both in silico and in vivo work to produce faster, more precise predictions for drug discovery research.
Our technology platform can work from raw data formats, applies robust feature selection methods, and conducts integrated analytics on siloed data and complex data types.